EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Glycosylated Delphinidins Decrease Chemoresistance to Temozolomide by Regulating NF-κB/MGMT Signaling in Glioblastoma

Diego Carrillo-Beltrán, Yessica Nahuelpan, Constanza Cuevas, Karen Fabres, Pamela Silva iD, Jimena Zubieta, Giovanna Navarro, Juan P Muñoz, María A Gleisner iD, Flavio Salazar-Onfray iD, Noemi Garcia-Romero iD, Angel Ayuso-Sacido und 2 weitere

Cells · 2025

DOI: 10.3390/cells14030179 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Diego Carrillo-Beltrán und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Virología Molecular, Instituto de Bioquímica y Microbiología, Facultad de Ciencias, Universidad Austral de Chile, Valdivia 5090000, Ch…. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, NF-kappa B, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Nacional de Investigación y Desarrollo, Fondecyt Postdoctorado, Fondecyt regular.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GB) is a highly malignant brain tumor with a poor prognosis, with a median survival of only 14.6 months despite aggressive treatments. Resistance to chemotherapy, particularly temozolomide (TMZ), is a significant challenge. The DNA repair enzyme MGMT and glioblastoma stem cells (GSCs) often mediate this resistance. Recent studies highlight the therapeutic potential of natural compounds, particularly delphinidins, found in deep purple berries. Delphinidins are known for their ability to inhibit NF-κB signaling, a critical pathway for GB progression, chemoresistance, and MGMT expression. Our research demonstrates that glycosylated delphinidins have potential adjuvant use in the treatment of GB, offering a promising natural strategy to combat TMZ resistance. Specifically, we observed that delphinidin 3,5 di-glucoside has potent anticancer effects when used alone. Meanwhile, delphinidin 3 glucoside acted in synergy with temozolomide to decrease cell viability, highlighting its potential as an adjuvant. It also exerted a faster and more sustained inhibition of NF-κB, highlighting its potential for long-lasting therapeutic effects. These findings open new avenues for targeted therapies against glioblastoma, particularly to overcome treatment resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideGlioblastomaNF-kappa BDrug Resistance, NeoplasmSignal TransductionAnthocyaninsDNA Repair EnzymesTumor Suppressor ProteinsDNA Modification MethylasesBrain NeoplasmsHumansCell Line, TumorGlycosylationCell SurvivalAnimals

Stichwörter der Autor:innen

GSCsNF-κBchemoresistancedelphinidinsglioblastomamethyl guanine methyl transferasetemozolomide

Substanzen

TemozolomideNF-kappa BAnthocyaninsDNA Repair EnzymesTumor Suppressor ProteinsMGMT protein, humanDNA Modification Methylases

Autor:innen und Institutionen

  • Laboratorio de Virología Molecular, Instituto de Bioquímica y Microbiología, Facultad de Ciencias, Universidad Austral de Chile, Valdivia 5090000, Chile.
  • Laboratorio de Biología Tumoral, Instituto de Bioquímica y Microbiología, Facultad de Ciencias, Universidad Austral de Chile, Valdivia 5090000, Chile.
  • Millennium Institute on Immunology and Immunotherapy, Facultad de Ciencias, Universidad Austral de Chile, Valdivia 5110566, Chile.
  • Laboratorio de Bioquímica, Departamento de Química, Facultad de Ciencias, Universidad de Tarapacá, Arica 1000007, Chile.
  • Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago 8380453, Chile.
  • Faculty of Experimental Sciences, Universidad Francisco de Vitoria, 28223 Madrid, Spain.

ORCID-Profile: Pamela Silva, María A Gleisner, Flavio Salazar-Onfray, Noemi Garcia-Romero

Förderung

  • Agencia Nacional de Investigación y Desarrollo
  • Fondecyt Postdoctorado
  • Fondecyt regular
  • Instituto de Salud Carlos III (ISCIII)

Zitieren

APA

Carrillo-Beltrán, D., Nahuelpan, Y., Cuevas, C., Fabres, K., Silva, P., Zubieta, J., Navarro, G., Muñoz, J. P., Gleisner, M. A., Salazar-Onfray, F., Garcia-Romero, N., Ayuso-Sacido, A., Martin, R. S., & Quezada-Monrás, C. (2025). Glycosylated Delphinidins Decrease Chemoresistance to Temozolomide by Regulating NF-κB/MGMT Signaling in Glioblastoma. Cells. https://doi.org/10.3390/cells14030179

Vancouver

Carrillo-Beltrán D, Nahuelpan Y, Cuevas C, Fabres K, Silva P, Zubieta J, et al. Glycosylated Delphinidins Decrease Chemoresistance to Temozolomide by Regulating NF-κB/MGMT Signaling in Glioblastoma. Cells. 2025. doi:10.3390/cells14030179

BibTeX
@article{CarrilloBeltrn2025,
  author = {Carrillo-Beltrán, Diego and Nahuelpan, Yessica and Cuevas, Constanza and Fabres, Karen and Silva, Pamela and Zubieta, Jimena and Navarro, Giovanna and Muñoz, Juan P and Gleisner, María A and Salazar-Onfray, Flavio and Garcia-Romero, Noemi and Ayuso-Sacido, Angel and Martin, Rody San and Quezada-Monrás, Claudia},
  title = {Glycosylated Delphinidins Decrease Chemoresistance to Temozolomide by Regulating NF-κB/MGMT Signaling in Glioblastoma},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14030179}
}
Kostenlos starten →